| Literature DB >> 31069039 |
Nikola Saulacic1, Benoit Schaller1.
Abstract
OBJECTIVES: Moderately-rough implant surface may improve implant therapy in terms of bone integration, but the increased surface roughness might affect the initiation and development of peri-implantitis. The aim of the present review was to compare the prevalence of peri-implantitis in implants with rough and turned (machined) implant surfaces.Entities:
Keywords: dental implant; osseointegrated dental implantation; peri-implantitis; systematic review; titanium
Year: 2019 PMID: 31069039 PMCID: PMC6498817 DOI: 10.5037/jomr.2019.10101
Source DB: PubMed Journal: J Oral Maxillofac Res ISSN: 2029-283X
Figure 1PRISMA flow diagram.
Included studies
| Study | Year of publication | Study design |
Follow-up | Number of implants/number of patients | Prevalence of peri-implantitis | Significance | Peri-implantitis definition | ||
|---|---|---|---|---|---|---|---|---|---|
| Turned implants | Rough surface implants | Turned implants | Rough surface implants | ||||||
| Astrand et al. [41] | 2004 |
Continuity of the study Astrand et al. [41].
| 3 |
73 (Brånemark System®; Nobel Biocare AB, Goteborg, Sweden)/ |
77 (TPS®; Straumann AG, Waldenburg, Switzerland)/ | 0 implants | 7 implants (9.1%) | The difference statistically significant | Infection including purulent discharge and bone loss |
| Moberg et al. [42] | 2001 | Prospective randomized study | 3 |
102 (Brånemark System®;Nobel Biocare AB, Goteborg, Sweden)/ |
106 (TPS®; Straumann AG, Waldenburg, Switzerland)/ | 1 implants | 3 implants | Not indicated | Peri-implant infection with bone reduction |
| Ravald et al. [43] | 2012 | Prospective randomized controlled study | 12 - 15 | 177 (Brånemark System®; Nobel Biocare AB, Goteborg, Sweden) | 176 (TPS®; Straumann AG, Waldenburg, Switzerland) | 9 implants (5%) | 10 implants (6%) | NR | Bone loss ≥ 2 mm and bleeding or pus on probing |
| Renvert et al. [44] | 2012 | Prospective clinical trial | 13 | 102/22 patients machine-etched (Brånemark System®; Nobel Biocare AB, Goteborg, Sweden) |
132 implants/19 patients | 12 implants (11.5%) | 9 implants (7.1%) | No difference in the incidence of peri-implantitis over a period of 13 years as an effect implant surface and design was found. | Peri-implantitis incidence was defined as bone loss ≥ 1 mm after 1 year, and with BOP or suppuration |
| Polizzi et al. [45] | 2013 | Retrospective study (both types of implants in the same patient) | 10 |
257 (Brånemark System®; Nobel Biocare AB, Goteborg, Sweden)/ |
243 moderately rough oxidized surfaced (TiUnite®; Nobel Biocare AB, Goteborg, Sweden)/ | 1 implant | 9 implants | Peri-implantitis diagnosed in 4 patients (4.2%) and 10 implants (2%), 9 being TiUnite® implants and 1 turned (significance not indicated) | Mucosal lesion associated with suppuration and deepened pockets but always accompanied by loss of supporting marginal bone (Lindhe and Meyle [20]) |
| Vandeweghe et al. [46] | 2016 | Retrospective study | At least 10 years in function (mean 172 [SD 42] months; range 120 to 252) |
76 (Southern Implant System®; Southern Implants, Irene, South Africa)/ |
121 moderately rough surface, obtained by sandblasting and chemical cleaning (Southern Implant System®; Southern Implants, Irene, South Africa)/ | NR | NR | Prevalence of peri-implantitis 4.1% in turned and moderately rough implants, with no significant difference between (P = 0.7) |
PD > 6 mm in combination with BOP/ |
| de Araújo Nobre and Malo [47] | 2014 | Case-control study | At least 1 year in function |
296 (Brånemark System®; Nobel Biocare AB, Goteborg, Sweden)/ |
1054 moderately rough oxidized surfaced (TiUnite®; Nobel Biocare AB, Goteborg, Sweden)/ | 74 (5.5)% | 196 (14.5)% |
Machined implant surface identified as a risk factor for peri-implant pathology | Peri-implant pathology was diagnosed through: peri-implant pockets ≥ 5 mm diagnosed through probing of the peri-implant sulcus/pocket using a probe calibrated to 0.25 N, bleeding on probing; bone loss visible to X-ray; and attachment loss equal to or greater than 2 mm |
TPS = titanium plasma sprayed; BOP = bleeding on probing; PD = probing depth; NR = not reported.
Clinical parameters
| Study | Plaque | Bleeding on probing | Suppuration | Pocket probing depth | ||||
|---|---|---|---|---|---|---|---|---|
| Turned | Rough | Turned | Rough | Turned | Rough | Turned | Rough | |
| Astrand et al. [41] | 7.9% | 9.1% | 11.9% | 7.5% | Not reported | Not reported | Not reported | Not reported |
| Moberg et al. [42] | 37% | 36% | 14% | 20% | Not reported | Not reported |
≤ 3 mm: 96 % |
≤ 3 mm: 97.5%; |
| Ravald et al. [43] |
Maxilla: 28 (31)%; |
Maxilla: 18 (22)%; |
Maxilla: 54 (18)%; |
Maxilla: 45 (12)%; | Not reported | Not reported |
1 to 3 mm: |
1 to 3 mm: |
| Renvert et al. [44] | 61.5% | 64.3% | 89.7% | 82.1% | 3.8% | 1.2% | 3.1 (2.2) mm | 2.6 (2.3) mm |
| Polizzi et al. [45] | 29 (29.2)% | 14 (14.9)% | Not reported | Not reported | 1 (1.1)% | 4 (4.3)% |
Verstibular: 2.51 (0.97) mm; |
Verstibular: 2.53 (0.82) mm; |
| Vandeweghe et al. [46] | Not reported | Not reported |
47.2% | Not reported | Not reported | Not reported | 3.64 (0.96) mm (range 1.25 to 7.25 mm) | |
| de Araújo Nobre and Malo [47] | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
Patient related factors
| Author | Smoking | Periodontitis |
Preopearative | Rheumatologic condition | Diabetes | Osteoporosis | Immunosuppressive therapy |
|---|---|---|---|---|---|---|---|
| Astrand et al. [41] |
Excluded > 20/day | Excluded | Yes | Excluded | Excluded | Excluded | Excluded |
| Moberg et al. [42] | Excluded | Excluded | Not specified | Excluded | Excluded | Excluded | Excluded |
| Ravald et al. [43] | 8 patients | Apparently excluded | Not specified | 9 patients | 5 patients | No | 8 patients |
| Renvert et al. [44] | 16 patients current and past | Included | Not specified | 0 patients | 0 patients | 3 patients | Asthma 3, bronchitis 1, allergy 2 patients |
| Polizzi et al. [45] |
Included 55.2%; | 1% | Not specified | Excluded | 2.1% | 1% | 1% |
| Vandeweghe et al. [46] | 5 patients | Excluded | Not specified | Excluded | Excluded | Excluded | Excluded |
| de Araújo Nobre and Malo [47] |
Smoker 1.1%; | 60.5% | Not specified | 10.7% | 9.7% | 0 % | 2% |
Assessment of the risk of bias
| Author |
Random |
Allocation | Blinding |
Incomplete |
Selective |
Other |
|---|---|---|---|---|---|---|
| Astrand et al. [41] | + | ? | ? | + | + | + |
| Moberg et al. [42] | ? | ? | ? | + | ? | + |
| Ravald et al. [43] | ? | - | - | + | + | ? |
| Renvert et al. [44] | ? | ? | ? | + | + | + |
| Polizzi et al. [45] | ? | ? | ? | + | + | ? |
| Vandeweghe et al. [46] | ? | ? | ? | + | + | + |
| de Araújo Nobre and Malo [47] | ? | ? | ? | - | - | + |
+ = low risk of bias; ? = unclear risk of bias; - = high risk of bias.